Objective-To examine the relationship between baroreflex sensitivity and neurohormonal activation in patients with an acute myocardial infarction. Methods-Baroreflex sensitivity, plasma noradrenaline, atrial natriuretic factor, endothelin-1, and plasma renin activity were measured in 37 male patients about 10 days after their first myocardial infarction, and in 15 healthy controls. Baroreflex sensitivity was assessed from the regression line relating the change in RR interval to the change in systolic blood pressure following an intravenous bolus injection of phenylephrine. The measurements were repeated after a follow up of three months. Results-There was a significant inverse correlation between baroreflex sensitivity and plasma noradrenaline measured before hospital discharge (r = -0.43, P < 0.01). Patients with increased plasma noradrenaline ( > 2SD above the mean of the age matched control group) had significantly lower baroreflex sensitivity than patients with normal plasma noradrenaline (8.7 (SD 4.6) v 12-1 (6.1) ms/mm Hg, P < 0.05). The change in baroreflex sensitivity during the follow up showed a significant inverse correlation with the change of plasma noradrenaline (r = -0 450, P < 0.01). Furthermore, when patients with increased plasma noradrenaline before hospital discharge were analysed separately, baroreflex sensitivity at three months in patients in whom plasma noradrenaline had decreased to normal values was significantly higher than in patients in whom plasma noradrenaline had remained increased (14.6 (5.7) v 8-1 (8.1) ms/mm Hg, P < 0.05). On the other hand, baroreflex sensitivity was not related to the levels of plasma atrial natriuretic factor, plasma endothelin-1, or plasma renin activity. Neither was any relationship found between change in baroreflex sensitivity and change in plasma atrial natriuretic factor, endothelin-1, or plasma renin activity during the follow up.
noradrenaline ( > 2SD above the mean of the age matched control group) had significantly lower baroreflex sensitivity than patients with normal plasma noradrenaline (8.7 (SD 4.6) v 12-1 (6.1) ms/mm Hg, P < 0.05). The change in baroreflex sensitivity during the follow up showed a significant inverse correlation with the change of plasma noradrenaline (r = -0 450, P < 0.01). Furthermore, when patients with increased plasma noradrenaline before hospital discharge were analysed separately, baroreflex sensitivity at three months in patients in whom plasma noradrenaline had decreased to normal values was significantly higher than in patients in whom plasma noradrenaline had remained increased (14.6 (5.7) v 8-1 (8.1) ms/mm Hg, P < 0.05). On the other hand, baroreflex sensitivity was not related to the levels of plasma atrial natriuretic factor, plasma endothelin-1, or plasma renin activity. Neither was any relationship found between change in baroreflex sensitivity and change in plasma atrial natriuretic factor, endothelin-1, or plasma renin activity during the follow up.
Conclusions-The impairment baroreflex sensitivity after myocardial infarction was associated with increased concentration of plasma noradrenaline, that is, sympathetic activation, but not with plasma atrial natriuretic factor, endothelin-1, or plasma renin activity. Baroreflex sensitivity provides information about cardiac vagal control as well as about the balance of cardiac sympatheticparasympathetic regulation.
(Br HeartJ' 1995; 74:21-26) Keywords: atrial natriuretic factor; autonomic nervous system; catecholamines; endothelin-1; myocardial infarction; renin Acute myocardial infarction results in an impairment of cardiac autonomic regulation' 2 as well as in a wide spectrum of neurohormonal activation, including increased plasma noradrenaline,3 4 atrial natriuretic factor,5 endothelin-1,6 and renin activity.7 Impairment of cardiac autonomic regulation, that is, low baroreflex sensitivity, in patients with recent myocardial infarction, has been found to be related to poor prognosis because of cardiac electrical instability leading to ventricular tachyarrhythmias and sudden cardiac death.8-'0 Neurohormonal activation in patients with myocardial infarction has also been associated with complications and excessive mortality."1-'4
The mechanism responsible for the impairment of baroreflex sensitivity in patients with acute myocardial infarction has not yet been defined. It has not been found to be related to size, type, or location of myocardial infarction, nor to the severity of cardiac dysfunction.89 15 One possibility is that impairment of baroreflex sensitivity might be associated with neurohormonal activation. So far, however, there are no data available on this subject. Thus the objective of this study was to evaluate the relationship between baroreflex sensitivity and neurohormonal activation in patients with acute myocardial infarction.
Methods

SUBJECTS AND STUDY PROTOCOL
The study population consisted of 37 men aged 53-8 (SD 9 2) years (range 32-68) recovering from their first myocardial infarction. Myocardial infarction was diagnosed according to the criteria of the World Health Organisation. 16 The location of myocardial infarction was anterior in 16 patients (46%) and inferior in 12 patients (30%). Twenty two patients (61%) had Q wave infarction and 15 Hartikainen, Fyhrquist, Tahvanainen, Lansimies, Pydrdld patients (29%) were treated with thrombolytic therapy. f, Blockers were used by 34 patients (94%), calcium channel blockers by five (14%), and oral nitrates by 31 (84%). Medication was not changed during the follow up. Patients with diabetes mellitus, Parkinson's disease, chronic alcoholism, and atrial fibrillation were excluded. In addition, a control group of 15 age matched healthy male volunteers not belonging to hospital personnel was recruited. The mean age of the controls was 54-6 (9 1) years (range 37-67).
Baroreflex sensitivity was determined before discharge from the hospital, about 10 days after the myocardial infarction. Before the measurement of baroreflex sensitivity, blood samples were taken for the analysis of plasma noradrenaline, atrial natriuretic factor, endothelin-1, and plasma renin activity. In addition, left ventricular ejection fraction was assessed by echocardiography. The measurement of baroreflex sensitivity and hormone analyses were repeated three months after the myocardial infarction. The control group was studied with the same protocol as patients, with the exception that hormone analyses were performed only once.
The To assess the reproducibility of the assessment of baroreflex sensitivity, measurements carried out in the control group with three month intervals were compared. The two measurements of baroreflex sensitivity showed a high correlation (r=-0-903, P< 0.001) and the coefficient of variation (the standard deviation of the mean difference divided by the absolute mean of the two measurements x 100)19 was 7-4%.
PLASMA HORMONE ANALYSES
Blood samples for the plasma hormone analyses were taken after an overnight fast through a Teflon cannula in an antebrachial vein. After the insertion of the cannula the patients rested in the supine position for 30 minutes. Blood was drawn into prechilled tubes and placed on ice. Plasma was separated within 20 minutes at 40, frozen immediately, and stored at -70°C until assay. Plasma noradrenaline concentrations were analysed by high performance liquid chromatography (HPLC) Table 1 shows that plasma noradrenaline concentration was higher in patients than in controls at hospital discharge (P < 0 001; fig 1) as ANF, atrial natriuretic factor; BRS, baroreflex sensitivity. Measurements before hospital discharge (Discharge) and 3 months after MI (3 months). *P < 0 05; **P < 0-001 v controls (two tailed Student's t test); tP < 0 05; fP < 0-001 v hospital discharge (paired t test). well as at three months after myocardial infarction. No significant change was observed in plasma noradrenaline during the follow up. Patients had higher concentrations of plasma atrial natriuretic factor than the control group at hospital discharge (P < 0 05), but not at three months. Plasma atrial natriuretic factor decreased significantly during the follow up. Plasma endothelin-1 before hospital discharge was also higher in patients than in controls (P < 0 001). It decreased during the three month period, but still remained higher than in the controls at three months after myocardial infarction (P < 0 05). Plasma renin activity in controls and patients did not differ at hospital discharge or at three months. No significant change in plasma renin activity was found during the follow up.
RELATIONSHIP BETWEEN BAROREFLEX SENSITIVITY AND PLASMA HORMONES Baroreflex sensitivity measured before hospital discharge showed an inverse correlation with plasma noradrenaline in univariate analysis (r = -0J43, P < 0 01, fig 2) . This correlation remained significant (P < 0.05) when adjusted for age, size, location and type of infarction, thrombolytic therapy, medication, resting heart rate, resting blood pressure, and left ventricular ejection fraction. In order to study the relationship between baroreflex sensitivity and plasma noradrenaline more comprehensively patients were divided into two Plasma noradrenaline (mmol/l) Figure 2 The relationship between baroreflex sensitivity (BRS) and plasma noradrenaline concentration in patients with acute myocardial infarction before the hospital discharge. The regression line and 95% confidence intervals are shown.
groups by using 2 SD above the mean plasma noradrenaline for the controls (2-3 nmol/l) as the cut off value (fig 1) . Accordingly, patients with plasma noradrenaline > 2 3 nmol/l were considered as a group with increased plasma noradrenaline, and those with values of <2-3 nmol/l as a group with normal plasma noradrenaline. Patients with increased plasma noradrenaline had lower baroreflex sensitivity than patients with normal plasma noradrenaline (P < 0.05, table 2). The change in baroreflex sensitivity showed an inverse correlation with the change in plasma noradrenaline during the three month follow up in univariate analysis (r = -0A45, P < 0 01, fig 3) , as well as in multivariate analysis adjusting for age (P < 0.01). In addition, we studied in more detail the relationship between changes in baroreflex sensitivity and plasma noradrenaline in patients with increased plasma noradrenaline before hospital discharge. Patients in whom plasma noradrenaline decreased to normal values during the follow up had higher baroreflex sensitivity at three months than patients in whom plasma noradrenaline remained persistently elevated (14 6 (5 7) v 8d1 (8.1) ms/mm Hg, P < 0.05, fig 4) , that is, normalisation of 6 9 (2 6) ANF, atrial natriuretic factor; BRS, baroreflex sensitivity. Plasma noradrenaline, ANF, endothelin, and plasma renin activity were divided into two groups (normal and increased) at 2SD above the mean hormone activity of the control group. *P < 0 05 v the group with increased plasma noradrenaline (analysis of covariance). Figure 3 The relationship between the change in baroreflex sensitivity (BRS) and change in plasma noradrenaline during three months of follow up after myocardial infarction. The regression line and 95% confidence intervals are shown. Figure 4 Baroreflex sensitivity (BRS) and plasma noradrenaline measured three months after myocardial infarction in patients with increased plasma noradrenaline (> 2-3 nmolll) before hospital discharge. The patients were divided into two groups; patients in whom plasma noradrenaline had returned to normal during the three months (0) and patients with persistently increased plasma noradrenaline (0) muscles.'0 Thus it can be assumed that impairment of baroreflex sensitivity following myocardial infarction results in attenuation of sma noradrenaline was associated with a the tonic inhibitory signals responsible for the overy of baroreflex sensitivity.
reduction of efferent sympathetic activity. As Plasma atrial natriuretic factor, endothelin-a consequence, the level of tonic sympathetic and plasma renin activity did not show any activity becomes increased. In this case ;nificant correlations with baroreflex sensi-impairment of the baroreflex would be the ity, either in univariate or in multivariate mechanism responsible for the increased alyses. When patients were dichotomised at plasma noradrenaline after myocardial infarc-SD above the mean of the control group tion.
18 nglml for plasma atrial natriuretic factor, A third possibility is that baroreflex sensi-) pg/ml for plasma endothelin-1, and 4-3 tivity and plasma noradrenaline are not /ml for plasma renin activity) baroreflex directly dependent on each other, but that isitivity in patients with increased and nor-they share a common underlying determinant l levels of hormone activity did not differ which accounts for the concomitant impairim each other ( shown to be related to excessive mortality caused by cardiac arrhythmias. We did not find any significant relationship between baroreflex sensitivity and plasma concentrations of atrial natriuretic factor, endothelin-1, or plasma renin activity, neither was the change in baroreflex sensitivity during the three month follow up related to changes in plasma atrial natriuretic factor, endothelin-1, or plasma renin activity. Previous studies on patients with acute myocardial infarction have shown that the level of plasma atrial natriuretic factor, endothelin-1, and renin activity correlate with the extent of left ventricular dysfunction.35-7 On the other hand, earlier studies have failed to show any significant relationship between baroreflex sensitivity and cardiac systolic function in patients with myocardial infarction.89 15 The concept that the mechanism of impairment of baroreflex sensitivity and plasma atrial natriuretic factor activation in myocardial infarction is different is further reinforced by the fact that, although both low baroreflex sensitivity and raised plasma atrial natriuretic factor are related to increased mortality, the mechanism of death seems to be different; patients with increased plasma atrial natriuretic factor tend to die because of heart failure," whereas mortality associated with low baroreflex sensitivity is not ascribed to heart failure but to ventricular arrhythmias and sudden cardiac death. 8 sitivity, but calcium channel blockers have been reported to have no significant effect.37 In our study plasma noradrenaline remained a significant determinant of baroreflex sensitivity when adjusted for medication. Thus it is very unlikely that medication had an important effect on the relationship between baroreflex sensitivity and plasma noradrenaline.
IMPLICATIONS OF THE STUDY
The impairment of cardiac autonomic regulation associated with acute myocardial infarction, as well as cardiac autonomic regulation in general, is a complex phenomenon. Cardiac function is influenced by both sympathetic and parasympathetic nervous systems and particularly by the interaction between the two. The complexity becomes evident in this study, in which baroreflex sensitivity, an index traditionally used to quantify cardiac parasympathetic regulation, was found to be related to plasma noradrenaline, a marker of sympathetic activation. This does not belie the concept that heart rate changes caused by baroreceptor stimulation are primarily the result of changes in cardiac parasympathetic activity. However, we do suggest that baroreflex sensitivity is not entirely divorced from sympathetic nervous system activity. Accordingly, instead of interpreting baroreflex sensitivity as a pure indicator of cardiac parasympathetic regulation, it should be considered as a marker of cardiac sympatheticparasympathetic interaction.
CONCLUSIONS
In conclusion, the impairment of baroreflex sensitivity as a consequence of myocardial infarction was found to be associated with increased sympathetic activation, but not with the concentrations of plasma atrial natriuretic factor, endothelin-1, or plasma renin activity. We hypothesise that, in addition to cardiac vagal regulation, baroreflex sensitivity provides information about cardiac sympatheticparasympathetic interaction.
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